Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: a randomised, double-blind, placebo-controlled trial.

Lisse DecraeckerDanny De LoozeDavid P HirschHeiko De SchepperJoris ArtsPhilip CaenepeelAlbert J BredenoordJeroen KolkmanKoen BellensKim Van BeekFedrica PiaWilly PeetermansTim VanuytselAlexandre Denadai-SouzaAnn BelmansGuy E Boeckxstaens

Published in: Gut (2024)

The study protocol was approved by the local ethics committee of each study site (EudraCT number: 2013-001199-39; ClinicalTrials.gov identifier: NCT01908465).

Keyphrases

double blind
study protocol
placebo controlled
irritable bowel syndrome
clinical trial
randomized controlled trial
open label
public health
phase ii
combination therapy
big data
machine learning
deep learning
global health